Anti-inflammatory Agents: Present and Future

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674

Biologic basis for interleukin-1 in disease.

Dinarello, C. (1996) · Blood · doi:10.1182/blood.v87.6.2095.bloodjournal8762095 · Cited by 4,344

Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein

Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641

Immunological and inflammatory functions of the interleukin-1 family

Dinarello, C. A. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132612 · Cited by 3,466

Thioredoxin-interacting protein links oxidative stress to inflammasome activation

Zhou, R., Tardivel, A., Thorens, B., Choi, I., & Tschopp, J. (2010) · Nature Immunology · doi:10.1038/ni.1831 · Cited by 2,708

The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina

Liuzzo, G., Biasucci, L. M., Gallimore, J. R., Grillo, R. L., Rebuzzi, A. G., Pepys, M. B., & Maseri, A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408183310701 · Cited by 2,354

The Effect of Dietary Supplementation with n—3 Polyunsaturated Fatty Acids on the Synthesis of Interleukin-1 and Tumor Necrosis Factor by Mononuclear Cells

Endres, S., Ghorbani, R., Kelley, V. E., Georgilis, K., Lonnemann, G., van der Meer, J. W. M., Cannon, J. G., Rogers, T. S., Klempner, M. S., Weber, P. C., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902023200501 · Cited by 1,911

Histone deacetylases and cancer: causes and therapies

Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866

Interleukin-1-receptor antagonist in type 2 diabetes mellitus

Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798

Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle–Wells syndrome

Hoffman, H. M., Mueller, J. L., Broide, D. H., Wanderer, A. A., & Kolodner, R. D. (2001) · Nature Genetics · doi:10.1038/ng756 · Cited by 1,679

Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1.

Dinarello, C. A., Cannon, J. G., Wolff, S. M., Bernheim, H. A., Beutler, B., Cerami, A., Figari, I. S., Palladino, M. A., & O'Connor, J. V. (1986) · The Journal of experimental medicine · doi:10.1084/jem.163.6.1433 · Cited by 1,472

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.

Sampaio, E. P., Sarno, E. N., Gallily, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of Experimental Medicine · doi:10.1084/jem.173.3.699 · Cited by 1,191

Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets

Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller‐Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92172 · Cited by 1,113

Horror Autoinflammaticus: The Molecular Pathophysiology of Autoinflammatory Disease

Masters, S. L., Simon, A., Aksentijevich, I. A., & Kastner, D. L. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141627 · Cited by 1,083

Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets

Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller‐Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215318 · Cited by 1,006

An Autoinflammatory Disease with Deficiency of the Interleukin-1–Receptor Antagonist

Aksentijevich, I. A., Masters, S. L., Ferguson, P. J., Dancey, P., Frenkel, J., van Royen‐Kerkhof, A., Laxer, R. M., Tedgård, U., Cowen, E. W., Pham, T., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807865 · Cited by 981

Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence

Groß, O., Poeck, H., Bscheider, M., Dostert, C., Hannesschläger, N., Endres, S., Hartmann, G., Tardivel, A., Schweighoffer, E., Tybulewicz, V. L. J., et al. (2009) · Nature · doi:10.1038/nature07965 · Cited by 947

Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition

Goldbach‐Mansky, R. T., Garnes, N. D., Canna, S., Gelabert, A., Jones, J. H., Rubin, B. I., Kim, H. J., Brewer, C. C., Zalewski, C. K., Wiggs, E. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055137 · Cited by 923

Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

Pascual, V., Allantaz, F., Arce, E., Punaro, M., & Banchereau, J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050473 · Cited by 923

Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome

Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810787 · Cited by 869

Rapid Secretion of Interleukin-1β by Microvesicle Shedding

Mackenzie, A. B., Wilson, H. L., Kiss‐Toth, E., Dower, S., North, R. A., & Surprenant, A. (2001) · Immunity · doi:10.1016/s1074-7613(01)00229-1 · Cited by 862

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease

Hockly, E., Richon, V. M., Woodman, B., Smith, D. L., Zhou, X., Rosa, E., Sathasivam, K., Ghazi‐Noori, S., Mahal, A., Lowden, P. A. S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437870100 · Cited by 847

Differential requirement for the activation of the inflammasome for processing and release of IL-1β in monocytes and macrophages

Netea, M. G., Nold‐Petry, C. A., Nold, M. F., Joosten, L. A. B., Opitz, B., van der Meer, J. H. M., van de Veerdonk, F. L., Ferwerda, G., Heinhuis, B., Devesa, I., et al. (2008) · Blood · doi:10.1182/blood-2008-03-146720 · Cited by 787

Resolvin D1 binds human phagocytes with evidence for proresolving receptors

Krishnamoorthy, S., Recchiuti, A., Chiang, N., Yacoubian, S., Lee, C., Yang, R., Petasis, N. A., & Serhan, C. N. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907342107 · Cited by 752

Development of Chronic Inflammatory Arthropathy Resembling Rheumatoid Arthritis in Interleukin 1 Receptor Antagonist–Deficient Mice

Horai, R., Saijo, S., Tanioka, H., Nakae, S., Sudo, K., Okahara, A., Ikuse, T., Asano, M., & Iwakura, Y. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.2.313 · Cited by 752

A pilot study of IL-1 inhibition by anakinra in acute gout

So, A., De Smedt, T., Revaz, S., & Tschopp, J. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2143 · Cited by 727

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S. C., Carey, N., et al. (2008) · Biochemical Journal · doi:10.1042/bj20070779 · Cited by 713

The Inflammasome-Mediated Caspase-1 Activation Controls Adipocyte Differentiation and Insulin Sensitivity

Stienstra, R., Joosten, L. A. B., Koenen, T. B., van Tits, B. L. J. H., van Diepen, J. A., van den Berg, S. A. A., Rensen, P. C. N., Voshol, P. J., Fantuzzi, G., Hijmans, A., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.11.011 · Cited by 700

Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia.

Fong, Y., Tracey, K. J., Moldawer, L. L., HESSE, D. G., Manogue, K., Kenney, J. S., Lee, A. T., Kuo, G. C., ALLISON, A. C., & Lowry, S. F. (1989) · The Journal of Experimental Medicine · doi:10.1084/jem.170.5.1627 · Cited by 640

Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.

Charles, P., Elliott, M. J., Davis, D., Potter, A., Kalden, J., Antoni, C., Breedveld, F., Smolen, J., Eberl, G., Dewoody, K., et al. (1999) · Journal of Immunology · doi:10.4049/jimmunol.163.3.1521 · Cited by 614

Efficacy and safety of rilonacept (interleukin‐1 trap) in patients with cryopyrin‐associated periodic syndromes: Results from two sequential placebo‐controlled studies

Hoffman, H. M., Throne, M. L., Amar, N. J., Sebai, M., Kivitz, A. J., Kavanaugh, A., Weinstein, S. P., Belomestnov, P., Yancopoulos, G. D., Stahl, N., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23687 · Cited by 577

Nonclassical IL-1β Secretion Stimulated by P2X7 Receptors Is Dependent on Inflammasome Activation and Correlated with Exosome Release in Murine Macrophages

Qu, Y., Franchi, L., Nunez, G., & Dubyak, G. R. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.3.1913 · Cited by 563

Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome

Drenth, J. P. H., Cuisset, L., Grateau, G., Vasseur, C., van der Velde-Visser, S. D., de Jong, J. G. N., Beckmann, J. S., van der Meer, J. W. M., & Delpech, M. (1999) · Nature Genetics · doi:10.1038/9696 · Cited by 556

Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist

Hoffman, H. M., Rosengren, S., Boyle, D. L., Cho, J. Y., Nayar, J., Mueller, J. L., Anderson, J. P., Wanderer, A. A., & Firestein, G. S. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17401-1 · Cited by 552

Intraarticular injection of anakinra in osteoarthritis of the knee: A multicenter, randomized, double‐blind, placebo‐controlled study

Chevalier, X., Goupille, P., Beaulieu, A. D., Burch, F. X., Bensen, W., Conrozier, T., Lœuille, D., Kivitz, A., Silver, D., & Appleton, B. E. (2009) · Arthritis Care & Research · doi:10.1002/art.24096 · Cited by 545

Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro.

Dinarello, C. A., Ikejima, T., Warner, S. J. C., Orencole, S. F., Lonnemann, G., Cannon, J. G., & Libby, P. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.6.1902 · Cited by 537

Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.

Charles, P. J., Elliott, M. J., Davis, D., Potter, A. R., Kalden, J. R., Antoni, C., Breedveld, F. C., Js, S., Eberl, G., DeWoody, K. L., et al. (1999) · PubMed · Cited by 531

The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines

Leoni, F., Zaliani, A., Bertolini, G., Porro, G., Pagani, P., Pozzi, P., Donà, G., Fossati, G., Sozzani, S., Azam, T., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052702999 · Cited by 511

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

Garcia‐Manero, G., Yang, H., Bueso-Ramos, C., Ferrajoli, A., Cortes, J. E., Wierda, W. G., Faderl, S. H., Koller, C. A., Morris, G., Rosner, G. L., et al. (2007) · Blood · doi:10.1182/blood-2007-06-098061 · Cited by 461

A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients

Emsley, H. C. A. (2005) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.054882 · Cited by 444

Endogenous pro‐resolving and anti‐inflammatory lipid mediators: a new pharmacologic genus

Serhan, C. N., & Chiang, N. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707489 · Cited by 441

Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies

Major, E. O. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.080708.082655 · Cited by 437

Phospholipases C and A 2 control lysosome-mediated IL-1β secretion: Implications for inflammatory processes

Andrei, C., Margiocco, P., Poggi, A. D., Lotti, L. V., Torrisi, M. R., & Rubartelli, A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308558101 · Cited by 423

Interleukin-1 Blockade With Anakinra to Prevent Adverse Cardiac Remodeling After Acute Myocardial Infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot Study)

Abbate, A., Kontos, M. C., Grizzard, J. D., Biondi‐Zoccai, G., Tassell, B. W. V., Robati, R., Roach, L. M., Arena, R. A., Roberts, C. S., Varma, A., et al. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.12.059 · Cited by 418

An Autoinflammatory Disease Due to Homozygous Deletion of the IL1RN Locus

Reddy, S. T., Jia, S., Geoffrey, R., Lorier, R., Suchi, M., Broeckel, U., Hessner, M. J., & Verbsky, J. W. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809568 · Cited by 408

Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies

O’Connor, O. A., Heaney, M. L., Schwartz, L. B., Richardson, S., Willim, R. D., MacGregor‐Cortelli, B., Curly, T., Moskowitz, C. H., Portlock, C. S., Horwitz, S. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.9679 · Cited by 404

Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes

Larsen, C. M., Faulenbach, M., Vaag, A., Ehses, J. A., Donath, M. Y., & Mandrup-Poulsen, T. (2009) · Diabetes Care · doi:10.2337/dc09-0533 · Cited by 401

Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction

Ren, M., Leng, Y., Jeong, M. R., Leeds, P. R., & Chuang, D. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02406.x · Cited by 375

Converting enzyme-independent release of tumor necrosis factor α and IL-1β from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3

Coeshott, C. M., Ohnemus, C., Pilyavskaya, A., Ross, S., Wieczorek, M., Kroona, H., Leimer, A. H., & Cheronis, J. C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6261 · Cited by 365

Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist, Inhibits Apoptosis in Experimental Acute Myocardial Infarction

Abbate, A., Salloum, F. N., Vecile, E., Das, A., Hoke, N. N., Straino, S., Biondi‐Zoccai, G., Houser, J.-E., Qureshi, I., Ownby, E. D., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.740233 · Cited by 364

Rapid responses to anakinra in patients with refractory adult‐onset Still's disease

Fitzgerald, A. A., LECLERCQ, S. A., Yan, A., Homik, J., & Dinarello, C. A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21061 · Cited by 349

Mechanisms of caspase-1 activation by P2X7 receptor-mediated K+ release

Kahlenberg, J. M., & Dubyak, G. (2004) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00494.2003 · Cited by 346

Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve‐week, randomized, placebo‐controlled trial

Weinblatt, M. E., Kavanaugh, A., Burgos‐Vargas, R., Dikranian, A. H., Medrano-Ramírez, G., Morales‐Torres, J., Murphy, F. T., Musser, T. K., Straniero, N., Vicente‐Gonzales, A. V., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23992 · Cited by 343

Risk and the Efficacy of Antiinflammatory Agents: Retrospective and Confirmatory Studies of Sepsis

Eichacker, P. Q., Parent, C., Kalil, A. C., Esposito, C., Cui, X., Banks, S. M., Gerstenberger, E. P., Fitz, Y., Danner, R. L., & Natanson, C. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200204-302oc · Cited by 340

The Histone Deacetylase Inhibitor ITF2357 Reduces Production of Pro-Inflammatory Cytokines In Vitro and Systemic Inflammation In Vivo

Leoni, F., Fossati, G., Lewis, E. C., Lee, J.-K., Porro, G., Pagani, P., Modena, D., Moras, M. L., Pozzi, P., Reznikov, L. L., et al. (2005) · Molecular Medicine · doi:10.2119/2006-00005.dinarello · Cited by 337

Affinity-purified human Interleukin I is cytotoxic to isolated islets of Langerhans

Mandrup-Poulsen, T. R., Bendtzen, K., Nerup, J., Dinarello, C. A., Svenson, M., & Nielsen, J. H. (1986) · Diabetologia · doi:10.1007/bf02427283 · Cited by 324

Arterial Inflammation in Mice Lacking the Interleukin 1 Receptor Antagonist Gene

Nicklin, M. J. H., Hughes, D. E., Barton, J. L., Ure, J. M., & Duff, G. W. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.2.303 · Cited by 319

Caspase 1–independent activation of interleukin‐1β in neutrophil‐predominant inflammation

Gumá, M., Ronacher, L., Liu‐Bryan, R., Takai, S., Karin, M., & Corr, M. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24959 · Cited by 305

Inflammatory arthritis in caspase 1 gene–deficient mice: Contribution of proteinase 3 to caspase 1–independent production of bioactive interleukin‐1β

Joosten, L. A. B., Netea, M. G., Fantuzzi, G., Koenders, M. I., Helsen, M. M. A., Sparrer, H., Pham, C. T. N., van der Meer, J. W. M., Dinarello, C. A., & van den Berg, W. B. (2009) · Arthritis & Rheumatism · doi:10.1002/art.25006 · Cited by 304

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study

Terkeltaub, R. A., Sundy, J. S., Schumacher, H. R., Murphy, F. T., Bookbinder, S., Biedermann, S., Wu, R., Mellis, S. J., & Radin, A. R. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.108936 · Cited by 297

Interleukin-1β–Driven Inflammation Promotes the Development and Invasiveness of Chemical Carcinogen–Induced Tumors

Krelin, Y., Voronov, E., Dotan, S., Elkabets, M., Reich, E., Fogel, M., Huszar, M., Iwakura, Y., Segal, S., Dinarello, C. A., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2956 · Cited by 285

Osmotic regulation of cytokine synthesis in vitro.

Shapiro, L., & Dinarello, C. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.26.12230 · Cited by 280

Caspase-1-dependent processing of pro-interleukin-1β is cytosolic and precedes cell death

Brough, D., & Rothwell, N. J. (2007) · Journal of Cell Science · doi:10.1242/jcs.03377 · Cited by 265

Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.

Münch, J. L., Ständker, L., Adermann, K., Schulz, A., Schindler, M., Chinnadurai, R., Pöhlmann, S., Chaipan, C., Biet, T., Peters, T., et al. (2007) · Cell · doi:10.1016/j.cell.2007.02.042 · Cited by 261

ATP Acts as an Agonist to Promote Stimulus-Induced Secretion of IL-1β and IL-18 in Human Blood

Perregaux, D. G., McNiff, P. A., Laliberte, R., Conklyn, M. J., & Gabel, C. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.8.4615 · Cited by 256

Inflammation and the Activated Protein C Anticoagulant Pathway

Esmon, C. T. (2006) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-2006-939554 · Cited by 248

Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component

Lust, J. A., Lacy, M. Q., Zeldenrust, S. R., Dispenzieri, A. A., Gertz, M. A., Witzig, T. E., Kumar, S. K., Hayman, S. R., Russell, S. J., Buadi, F. K., et al. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.2.114 · Cited by 247

Pattern of interleukin‐1β secretion in response to lipopolysaccharide and ATP before and after interleukin‐1 blockade in patients with CIAS1 mutations

Gattorno, M., Tassi, S., Carta, S., Delfino, L., Ferlito, F., Pelagatti, M. A., D’Osualdo, A., Buoncompagni, A., Alpigiani, M. G., Alessio, M., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22842 · Cited by 247

Response to local inflammation of IL-1 beta-converting enzyme- deficient mice

Fantuzzi, G., Ku, G., Harding, M. W., Livingston, D. J., Sipe, J. D., Kuida, K., Flavell, R. A., & Dinarello, C. A. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.4.1818 · Cited by 232

Interleukin-1β and the Autoinflammatory Diseases

Dinarello, C. A. (2009) · New England Journal of Medicine · doi:10.1056/nejme0811014 · Cited by 228

Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra

Brenner, M., Ruzicka, T., Plewig, G., Thomas, P., & Herzer, P. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09404.x · Cited by 225

Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis

Paniagua, R. T., Sharpe, O., Ho, P. P.-K., Chan, S. M., Chang, A., Higgins, J. P., Tomooka, B. H., Thomas, F. M., Song, J. J., Goodman, S. B., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28546 · Cited by 214

α1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice

Lewis, E. C., Mizrahi, M. I., Toledano, M., DeFelice, N., Wright, J. L., Churg, A., Shapiro, L., & Dinarello, C. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807627105 · Cited by 192

IL-Converting Enzyme/Caspase-1 Inhibitor VX-765 Blocks the Hypersensitive Response to an Inflammatory Stimulus in Monocytes from Familial Cold Autoinflammatory Syndrome Patients

Stack, J. H., Beaumont, K. C., Larsen, P. D., Straley, K. S., Henkel, G., Randle, J. C. R., & Hoffman, H. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.4.2630 · Cited by 191

Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells

Archin, N. M., Eron, J. J., Palmer, S., Hartmann-Duff, A., Martinson, J., Wiegand, A. P., Bandarenko, N., Schmitz, J. L., Bosch, R. J., LANDAY, A. L., et al. (2008) · AIDS · doi:10.1097/qad.0b013e3282fd6df4 · Cited by 186

α-1-Antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood

Pott, G. B., Chan, E. D., Dinarello, C. A., & Shapiro, L. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0208145 · Cited by 185

Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model.

Bodar, E. J., van der Hilst, J. C. H., Drenth, J. P. H., van der Meer, J. W. M., & Simon, A. (2005) · PubMed · Cited by 166

Prostaglandin I2 Analogs Inhibit Proinflammatory Cytokine Production and T Cell Stimulatory Function of Dendritic Cells

Zhou, W., Hashimoto, K., Goleniewska, K., O’Neal, J. F., Ji, S., Blackwell, T. S., FitzGerald, G. A., Egan, K. M., Geraci, M. W., & Peebles, R. S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.2.702 · Cited by 165

Beneficial response to interleukin 1 receptor antagonist in traps

Simon, A., Bodar, E. J., van der Hilst, J. C. H., van der Meer, J. W. M., Fiselier, T. J. W., Cuppen, M. P. J. M., & Drenth, J. P. H. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.02.039 · Cited by 164

Alpha‐1‐antitrypsin inhibits human immunodeficiency virus type 1

Shapiro, L., Pott, G. B., & Ralston, A. H. (2001) · The FASEB Journal · doi:10.1096/fj.00-0311com · Cited by 163

Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis.

Ferretti, M., Casini–Raggi, V., Pizarro, T. T., Eisenberg, S. P., Nast, C. C., & Cominelli, F. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117345 · Cited by 154

The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F

Guerini, V., Barbui, V., Spinelli, O., Salvi, A., Dellacasa, C. M., Carobbio, A., Introna, M., Barbui, T., Golay, J., & Rambaldi, A. (2007) · Leukemia · doi:10.1038/sj.leu.2405049 · Cited by 153

Statins as antiinflammatory and immunomodulatory agents: A future in rheumatologic therapy?

Abeles, A. M., & Pillinger, M. H. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21521 · Cited by 151

A case of macrophage activation syndrome successfully treated with anakinra

Kelly, A., & Ramanan, A. V. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0919 · Cited by 147

Anti-angiogenesis Effect of the Novel Anti-inflammatory and Pro-resolving Lipid Mediators

Jin, Y., Arita, M., Zhang, Q., Saban, D. R., Chauhan, S. K., Chiang, N., Serhan, C. N., & Dana, R. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2462 · Cited by 144

ATP Treatment of Human Monocytes Promotes Caspase-1 Maturation and Externalization

Laliberte, R. E., Eggler, J. F., & Gabel, C. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.36944 · Cited by 138

HMG-CoA reductase inhibition induces IL-1β release through Rac1/PI3K/PKB-dependent caspase-1 activation

Kuijk, L. M., Beekman, J. M., Koster, J., Waterham, H. R., Frenkel, J., & Coffer, P. J. (2008) · Blood · doi:10.1182/blood-2008-03-144667 · Cited by 136

A Novel Targeted Inhibitor of the Alternative Pathway of Complement and Its Therapeutic Application in Ischemia/Reperfusion Injury

Huang, Y., Qiao, F., Atkinson, C., Holers, V. M., & Tomlinson, S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.11.8068 · Cited by 133

Histone Deacetylase Inhibitors: Molecular and Biological Activity as a Premise to Clinical Application

Santini, V., Gozzini, A., & Ferrari, G. (2007) · Current Drug Metabolism · doi:10.2174/138920007780655397 · Cited by 131

Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells

Larsen, L. H., Tonnesen, M., Rønn, S. G., Størling, J., Jørgensen, S. W., Mascagni, P., Dinarello, C. A., Billestrup, N., & Mandrup-Poulsen, T. R. (2007) · Diabetologia · doi:10.1007/s00125-006-0562-3 · Cited by 131

Statins differ in their ability to block NF-kB activation in human blood monocytes

Hilgendorff, A., Muth, H., Parviz, B., Staubitz, A., Haberbosch, W., Tillmanns, H., & Hölschermann, H. (2003) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp41397 · Cited by 130

The kinase inhibitor imatinib mesylate inhibits TNF-α production in vitro and prevents TNF-dependent acute hepatic inflammation

Wolf, A. M., Wolf, D. G. F., Rumpold, H. F., Ludwiczek, S., Enrich, B., Gastl, G. A., Weiß, G., & Tilg, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501758102 · Cited by 123

Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis

Paul, F., Waiczies, S., Wuerfel, J. T., Bellmann–Strobl, J., Dörr, J. R., Waiczies, H., Haertle, M., Wernecke, K. D., Volk, H., Aktaş, O., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001928 · Cited by 121

Oral valproic acid for epilepsy - long-term experience in therapy and side effects

Gerstner, T. A., Bell, N. V. T., & König, S. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.2.285 · Cited by 115

Anti-chemokine small molecule drugs: a promising future?

Proudfoot, A. E. J., Power, C., & Schwarz, M. K. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903535867 · Cited by 107

Pioglitazone Inhibits Toll-Like Receptor Expression and Activity in Human Monocytes and db/db Mice

Dasu, M. R. K., Park, S., Devaraj, S., & Jialal, I. (2007) · Endocrinology · doi:10.1210/en.2008-1757 · Cited by 103

The p38 mitogen-activated protein kinase pathway plays a critical role in thrombin-induced endothelial chemokine production and leukocyte recruitment

Marin, V., Farnarier, C., Grès, S., Kaplanski, S., Su, M. S. S., Dinarello, C. A., & Kaplanski, G. (2001) · Blood · doi:10.1182/blood.v98.3.667 · Cited by 102

Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury

Shein, N. A., Grigoriadis, N., Alexandrovich, A. G., Simeonidou, C., Lourbopoulos, A. I., Polyzoidou, E., Trembovler, V., Mascagni, P., Dinarello, C. A., & Shohami, E. (2009) · The FASEB Journal · doi:10.1096/fj.09-134700 · Cited by 98

Common genetic variation in the gene encoding interleukin-1-receptor antagonist (IL-1RA) is associated with altered circulating IL-1RA levels

Rafiq, S., Stevens, K., Hurst, A. J., Murray, A., Henley, W., Weedon, M. N., Bandinelli, S., Corsi, A. M., Guralnik, J. M., Ferruci, L., et al. (2007) · Genes & Immunity · doi:10.1038/sj.gene.6364393 · Cited by 92

Pexelizumab in ischemic heart disease: A systematic review and meta-analysis on 15,196 patients

Testa, L., van Gaal, W. J., Bhindi, R., Biondi‐Zoccai, G., Abbate, A., Agostoni, P., Porto, I., Andreotti, F., Crea, F., & BANNING, A. P. (2008) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2007.12.062 · Cited by 83

Bypassing Pathogen‐Induced Inflammasome Activation for the Regulation of Interleukin‐1β Production by the Fungal PathogenCandida albicans

van de Veerdonk, F. L., Joosten, L. A. B., Devesa, I., Mora-Montes, H. M., Kanneganti, T., Dinarello, C. A., van der Meer, J. W. M., Gow, N. A. R., Kullberg, B. J., & Netea, M. G. (2009) · The Journal of Infectious Diseases · doi:10.1086/597274 · Cited by 77

Schnitzler syndrome: Treatment failure to rituximab but response to anakinra

Eiling, E., Möller, M., Kreiselmaier, I., Brasch, J., & Schwarz, T. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.03.036 · Cited by 75

Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment.

Dinarello, C. A. (2005) · PubMed · Cited by 73

Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient.

Mitroulis, I., Papadopoulos, V. P., Konstantinidis, T. G., & Ritis, K. (2008) · PubMed · Cited by 66

Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease

Atweh, G. F., & Schechter, A. N. (2001) · Current Opinion in Hematology · doi:10.1097/00062752-200103000-00010 · Cited by 66

The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality

Stafylas, P. C., Sarafidis, P. A., & Lasaridis, A. N. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.06.005 · Cited by 64

The Peroxisome Proliferator-Activated Receptor γ Agonist Pioglitazone Improves Cardiometabolic Risk and Renal Inflammation in Murine Lupus

Zhao, W., Thacker, S. G., Hodgin, J. B., Zhang, H., Wang, J. H., Park, J. L., Randolph, A. E., Somers, E. C., Pennathur, S., Kretzler, M., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804341 · Cited by 59

Converting enzyme-independent release of tumor necrosis factor a and IL-1b from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3 (neutrophil elastaseycytokine processingyproteinase inhibitors)

Coeshott, C. M., Pilyavskaya, A., Ross, S., Wieczorek, M., Kroona, H., Leimer, A. H., & Cheronis, J. C. (1999) · Cited by 57

Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: A case report

Furlan, A., Botsios, C., Ruffatti, A., TODESCO, S., & Punzi, L. (2008) · Joint Bone Spine · doi:10.1016/j.jbspin.2007.07.010 · Cited by 53

Complete remission of severe idiopathic cold urticaria on interleukin-1 receptor antagonist (anakinra).

Bodar, E. J., Simon, A., de Visser, M., & van der Meer, J. W. M. (2009) · PubMed · Cited by 51

Human Mitogen-activated Protein Kinase CSBP1, but Not CSBP2, Complements a hog1 Deletion in Yeast

Kumar, S., McLaughlin, M. M., McDonnell, P., Lee, J. C., Livi, G. P., & Young, P. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.49.29043 · Cited by 50

Rab39a Binds Caspase-1 and Is Required for Caspase-1-dependent Interleukin-1β Secretion

Becker, C., Creagh, E. M., & O'Neill, L. A. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.046102 · Cited by 49

Searching for Disease Modifiers—PKC Activation and HDAC Inhibition—A Dual Drug Approach to Alzheimer's Disease that Decreases Aβ Production while Blocking Oxidative Stress

Kozikowski, A. P., Chen, Y., Tapadar, S., Lewin, N. E., Blumberg, P. M., Zhong, Z., D’Annibale, M. A., Wang, W., Shen, Y., & Langley, B. C. (2009) · ChemMedChem · doi:10.1002/cmdc.200900045 · Cited by 43

The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity

Stienstra, R., Joosten, L. A. B., Koenen, T. B., van der Meer, J. W. M., Tack, C. J., Kanneganti, T., & Netea, M. G. (2009) · Cytokine · doi:10.1016/j.cyto.2009.07.567 · Cited by 41

Non‐complementaemic urticarial vasculitis: successful treatment with the IL‐1 receptor antagonist, anakinra

Botsios, C., Sfriso, P., Punzi, L., & TODESCO, S. (2007) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740600938647 · Cited by 37

Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer

Graziano, F., Ruzzo, A., Canestrari, E., Loupakis, F., Santini, D., Rulli, E., Humar, B., Galluccio, N., Bisonni, R., Floriani, I., et al. (2008) · The Pharmacogenomics Journal · doi:10.1038/tpj.2008.16 · Cited by 31

Islets of Langerhans

Bauer, G. E. (1983) · doi:10.1007/978-1-349-06859-3_22 · Cited by 27

The Complement Inhibitor FUT-175 Suppresses T Cell Autoreactivity in Experimental Autoimmune Encephalomyelitis

Li, Q., Nacion, K. M., Bu, H., & Lin, F. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.081093 · Cited by 25

Indications de l’anakinra

Chauffier, K., London, J., Beaudouin, C., & Fautrel, B. (2009) · La Presse Médicale · doi:10.1016/j.lpm.2009.01.012 · Cited by 21

Regulatory roles for histone deacetylation in IL‐1β‐induced nitric oxide release in pancreatic β‐cells

Susick, L. L., Veluthakal, R., Suresh, M. V., Hadden, T. J., & Kowluru, A. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00171.x · Cited by 19

Activated protein C downregulates p38 mitogen-activated protein kinase and improves clinical parameters in an in-vivo model of septic shock

Nold‐Petry, C. A., Fischer, D., Richter, B., Blaheta, R. A., Pfeilschifter, J. M., Mühl, H., Schranz, D., Veldman, A., & Nold, M. F. (2007) · Thrombosis and Haemostasis · doi:10.1160/th07-01-0052 · Cited by 18

Lenalidomide and its role in the management of multiple myeloma

Falco, P., Cavallo, F., Larocca, A., Liberati, A. M., Musto, P., Boccadoro, M., & Palumbo, A. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.6.865 · Cited by 17

Cytokine modulation and suppression of liver injury by a novel analogue of thalidomide

Thiele, A., Bang, R., Gütschow, M., Rossol, M., Loos, S., Eger, K., Tiegs, G., & Hauschildt, S. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02423-8 · Cited by 13

Expression and localization of IL‐1β mRNA is interrelated with cytoskeletal rearrangement in monocytes stimulated by adherence: A light microscopy in situ hybridization study

Böcker, U., Sirenko, O. I., Morris, J., Sartor, R. B., Singer, M., Haskill, J. S., & Watson, J. (2001) · Immunology and Cell Biology · doi:10.1046/j.1440-1711.2001.01031.x · Cited by 12

Safety and efficacy of oral ITF2357 in patients with active systemic onset juvenile idiopathic arthritis

Vojinović, J., Dinarello, C. A., Furlan, A., Damjanov, N. S., D’Urzo, C., & Oldoni, T. (2009) · Cytokine · doi:10.1016/j.cyto.2009.07.391 · Cited by 7

Decreased whole blood cytokine production during a phase I trial of the histone deacetylase inhibitor ITF2357

Oldoni, T., Furlan, A., Monzani, M. V., & Dinarello, C. A. (2009) · Cytokine · doi:10.1016/j.cyto.2009.07.506 · Cited by 4

The anti-CD20 antibody Rituximab reduces the Th17 response

van de Veerdonk, F. L., Lauwerys, B., DiPadova, F., Marijnissen, R. J., Koenders, M. I., Gutierrez-Roelens, I., Durez, P., Netea, M. G., van der Meer, J. W. M., van den Berg, W. B., et al. (2009) · Cytokine · doi:10.1016/j.cyto.2009.07.412 · Cited by 1

Inflammation and tumor progression: signaling pathways and targeted intervention

Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 3,058

The interleukin-1 family: back to the future

Garlanda, C., Dinarello, C. A., & Mantovani, A. (2013) · Immunity · doi:10.1016/j.immuni.2013.11.010 · Cited by 1,945

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,812

Understanding the mechanism of IL-1β secretion

Lopez-Castejon, G., & Brough, D. (2011) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2011.10.001 · Cited by 1,519

The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives

Tsalamandris, S., Antonopoulos, A. S., Oikonomou, E., Papamikroulis, G.-A., Vogiatzi, G., Papaioannou, S., Deftereos, S., & Tousoulis, D. (2019) · European Cardiology Review · doi:10.15420/ecr.2018.33.1 · Cited by 1,381

A Comprehensive Review of Anti-Inflammatory Activity: Phytomedicines, In Vitro and In Vivo Models

Vasantha, G., Joel, K. J., & Madhuri, G. (2026) · International Journal of Zoological Investigations · doi:10.33745/ijzi.2026.v12i01.045

Novel Targets for Antiinflammatory and Antiarthritic Agents

Kulkarni, R., Achaiah, G., & Sastry, G. N. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206777698945 · Cited by 52

[Anti-inflammatory drugs : from old classical ones to biotherapies and JAK inhibitors].

Scheen, A. J. (2022) · PubMed · Cited by 1

A Systemic Review on Plant Based Anti-Inflammatory Agents

Prajapati Rahul1*, G. M. (2025) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.14993025

Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics

Li, P., Zheng, Y., & Chen, X. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00460 · Cited by 354